Podcast Interview: Chris Garabedian, CEO, AVI BioPharma

Article

In our latest podcast, Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.

Interview: Chris Garabedian

Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.

Recent Videos
Marcel Botha, 10XBeta
Marcel Botha, 10XBeta
Gameto - Addressing Regulatory Hurdles in iPSC-Based Fertility
Dr. Dina Radenkovic, CEO, Gameto
Recent Regulatory Impacts on the Pain-Management Space
Fred Aslan
Related Content
Credit: Yurii Kibalnik | stock.adobe.com

FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis

Davy James
April 30th 2025
Article

AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.

Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

FDA Approves Akeso’s PD-1 Monoclonal Antibody for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma

FDA Approves Akeso’s PD-1 Monoclonal Antibody for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma

Don Tracy, Associate Editor
April 25th 2025
Article

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced nasopharyngeal carcinoma.

Navigating Distrust: Pharma in the Age of Social Media

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
February 18th 2025
Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

AbbVie Submits Biologics License Application to FDA for Novel Serotype E Botulinum Neurotoxin in Moderate to Severe Glabellar Lines

AbbVie Submits Biologics License Application to FDA for Novel Serotype E Botulinum Neurotoxin in Moderate to Severe Glabellar Lines

Don Tracy, Associate Editor
April 24th 2025
Article

The submission is backed by clinical data from over 2,100 patients, including two pivotal Phase III trials in patients treated with trenibotulinumtoxinE for moderate to severe glabellar lines.

FDA Updates Prescribing Information for Bristol Myers Squibb’s Camzyos to Reduce Echocardiography Monitoring Requirements

FDA Updates Prescribing Information for Bristol Myers Squibb’s Camzyos to Reduce Echocardiography Monitoring Requirements

Don Tracy, Associate Editor
April 21st 2025
Article

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and expanding eligibility in patients with symptomatic New York Heart Association Class II-III obstructive hypertrophic cardiomyopathy.